Sozinibercept

Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats[1][2][3].

Product Specifications

CAS Number

[2568358-31-4]

Product Name Alternative

OPT 302; VGX-300

UNSPSC

12352203

Target

VEGFR

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/sozinibercept.html

Purity

98.52

Solubility

10 mM in DMSO

Smiles

[Sozinibercept]

Molecular Weight

(120.85 kDa)

References & Citations

[1]Lashkari K, et al. VGX-300, a ‘Trap’for VEGF-C and VEGF-D, Inhibits Choroidal Neovascularization and Vascular Leakage in a Mouse Model of Wet AMD[J]. Investigative Ophthalmology & Visual Science, 2015, 56 (7) : 4802-4802. |[2]Lashkari K, et al. VEGF-C and VEGF-D Blockade by VGX-300 Inhibits Choroidal Neovascularization and Leakage in a Mouse Model of wet AMD[J]. Investigative Ophthalmology & Visual Science, 2014, 55 (13) : 1823-1823. |[3]Turunen T, et al. VEGF-C and VEGF-D Inhibition by VGX-300 Effectively Reduces Leukocyte Adhesion and Vascular Leakage in the STZ-Rat Model of Diabetic Retinal Edema[J]. Investigative Ophthalmology & Visual Science, 2019, 60 (9) : 3667-3667.